Takeda Pharmaceuticals America, Inc.
Cambridge, MA Part of Takeda Pharmaceutical Company LIMITED
- UEI
- ENNFDLWFC6L1
- CAGE
- 3FLV7
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Takeda Pharmaceutical Company Limited, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
WZM4GN1RQAK9
-
Parent
WZM4GN1RQAK9
- SAM.gov registration date
- Physical address
- 40 Landsdowne St, Cambridge, MA 02139, USA
- Website
- takedaoncology.com
- Founded
- 1993
- Employees
- 1K-5K
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $350,619 |
| FY2025 | $506,156 |
| FY2024 | $712,596 |
| FY2023 | $464,980 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $250,184 | |
| 2 | Department of Justice | $100,435 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Takhzyro 150 MG | Veterans Integrated Service Network 5 (VHA) | $0 | |
| Takhzyro 150 MG | Veterans Integrated Service Network 5 (VHA) | $38,098 | |
| Takhzyro 150 MG | Veterans Integrated Service Network 5 (VHA) | $38,098 | |
| Gattex 5 MG | Veterans Integrated Service Network 5 (VHA) | $34,605 | |
| Takhzyro 150 MG | Veterans Integrated Service Network 5 (VHA) | $38,098 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Foundation Care LLC | Chesterfield, MO | 456110 Pharmacies and Drug Retailers |
| Daiichi Pharmaceutical Corp | Bernards, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Centocor Ortho Biotech Inc. | Horsham, PA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Biologics By Mckesson | Cary, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Bristol-Myers Squibb Company | Lawrence Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Takeda Pharmaceuticals America, Inc., a foreign-owned subsidiary of Japan-based Takeda Pharmaceutical Company Limited, supplies specialty oncology pharmaceuticals to the federal government exclusively as a prime contractor through GSA Federal Supply Schedule and blanket purchase agreement vehicles, with no small business set-asides and no subcontract footprint. The company is a large, for-profit pharmaceutical manufacturer headquartered in Cambridge, Massachusetts, competing on a full-and-open basis in NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals).
Takeda's federal business concentrates on a single product line: ICLUSIG (ponatinib), a targeted cancer therapy for chronic myeloid leukemia and acute lymphoblastic leukemia, supplied in multiple dosage strengths (10 milligram through 45 milligram tablets). Recent representative work includes a $173.7 million delivery order from Veterans Integrated Service Network 20 for ICLUSIG 30mg tablets (May 2024), a $160.4 million delivery order from VISN 20 for ponatinib 30mg tablets (April 2022), a $153.4 million delivery order from VISN 22 for ICLUSIG 45mg tablets (October 2022), and recurring smaller orders ranging from $13,000 to $43,000 placed by nine distinct VA Veterans Integrated Service Networks and the Federal Correctional Complex Florence for emergency and routine pharmaceutical supply. All work is priced firm fixed-price with no set-aside designation.
The Department of Veterans Affairs dominates Takeda's federal customer base. Veterans Integrated Service Network 12 anchors the portfolio by potential value at $3.31 billion combined across 15 awards, while VISN 20 leads by award count at 40 orders totaling $2.7 million. VISN 5, VISN 9, VISN 22, and the VA National Acquisition Center collectively account for an additional $1.06 billion in potential value. Together, these five customers represent 100 percent of the potential-value ranking and 84 percent of award count. The Federal Correctional Complex Florence represents the only non-VA federal customer, with seven small delivery orders totaling $129 thousand for foundation care pharmaceutical chemotherapy. No other federal agencies appear in the footprint.
Takeda's federal work runs through three parent vehicles, all GSA-administered. The Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) is the broadest vehicle, carrying a $2.89 billion ceiling through September 2030 (awarded September 2025) and supporting 146 task orders with $185.3 million combined potential value. Two single-award blanket purchase agreements sit beneath that schedule: one established October 4, 2024, with a $123.5 million ceiling through September 2025, and a newer agreement awarded March 18, 2026, with an $851.9 million ceiling through March 2027, with four one-year option periods. The March 2026 BPA replaced the October 2024 instrument and carries recent call orders (July through August 2026) for TAKHZYRO 150 milligram and GATTEX 5 milligram products at individual call values between $34,600 and $38,100.
Activity has grown from 13 awards in 2022 to a peak of 31 awards in 2024, declining to 20 awards in 2025 and 13 in 2026 year-to-date. The source does not surface a recompete cliff or awards facing ultimate completion inside the next twenty-four months. Takeda has operated as a federal vendor since at least August 2003, based on the award date range in the source, with consistent ordering patterns across VA medical centers nationwide. Place of performance centers on Earth City, Missouri, and Cambridge, Massachusetts. The vendor holds no grants, maintains no subcontract relationships, and competes entirely through the VA's standardized pharmaceutical procurement apparatus without pursuing set-asides or teaming arrangements.
Quick answers
Is Takeda Pharmaceuticals America, Inc. registered in SAM.gov?
Yes. Takeda Pharmaceuticals America, Inc.'s SAM.gov registration is active through October 1, 2027.
What is Takeda Pharmaceuticals America, Inc.'s CAGE code?
Takeda Pharmaceuticals America, Inc.'s CAGE code is 3FLV7, and its Unique Entity ID (UEI) is ENNFDLWFC6L1.
Which contract vehicles does Takeda Pharmaceuticals America, Inc. hold?
Takeda Pharmaceuticals America, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Takeda Pharmaceuticals America, Inc. received in federal contracts?
Federal contracts obligated $506,156 to Takeda Pharmaceuticals America, Inc. in fiscal year 2025 and $2,034,351 in fiscal years 2023 through 2027.
How does Takeda Pharmaceuticals America, Inc. rank among federal contractors?
Takeda Pharmaceuticals America, Inc.'s parent company, Takeda Pharmaceutical Company Limited, ranked #47 in NAICS 325412, #58 in PSC 6505 and #65 in NAICS 3254 in FY2025.
What is Takeda Pharmaceuticals America, Inc.'s most recent federal award?
Takeda Pharmaceuticals America, Inc.'s most recent federal contract award is Takhzyro 150 MG (36C24526N0839), from Veterans Integrated Service Network 5 (VHA), on August 27, 2026.
On GovTribe
See Takeda Pharmaceuticals America, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors